PR Newswire TechnologyCodex · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 08-25 22:00:00(美东 10:00)·⟳ 抓取 08-25 22:00:38 +38s·⚡ 决策 08-26 02:58:12 +4h57m·62.7 天前
Leidos获美国海军健康研究中心5600万美元行为健康研究合同
合同为真实正面订单,但金额相对Leidos收入和市值太小,且公司近期季度单季订单规模约50亿美元,本次5600万美元合同难以形成足够短线预期差;未取得真实可交易报价和内部先例验证,不能输出ENTER。
📄 原文PR Newswire Technology↗ 原文
RESTON, Va., Aug. 25, 2026 /PRNewswire/ -- Leidos (NYSE:LDOS) was recently awarded a contract by the Naval Health Resea…
不做 Leidos Holdings, Inc.(LDOS.US)
5600万美元合同方向正面但年化收入贡献约0.06%,相对公司172亿美元收入和近期50亿美元单季订单太小;缺少实时stock_quote和event_study支持,不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Leidos获得NHRC 5600万美元、66个月合同,利好方向明确但量级很小:总额约占2025财年收入0.33%,年化约占0.06%,相对近期单季50亿美元订单也不突出。该事件更像常规政府服务合同披露,不足以支撑盘中追买LDOS.US。
🔎 新鲜度:最早出现 2026-08-25 · 扩散 low · price-in 风险 medium ↗
消息传播链
- Leidos发布获NHRC 5600万美元、66个月合同的新闻稿。
关键理由
- 合同确认Leidos在军方健康研究和战备支持领域延续客户关系。
- 量级句:2025财年收入约172亿美元,本次合同总额5600万美元、66个月年化约1018万美元,仅约占年收入0.06%,总额约占市值0.32%。
主要风险
- 合同金额未披露利润率和年度确认节奏,且规模相对公司收入与订单池过小,短线股价弹性有限。
- 未能使用stock_quote核实实时价格、买卖盘和20日抢跑情况,因此不能设定入场价。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-04 · 影响 weakens
公司近期单季订单约50亿美元、年收入约172亿美元,本次5600万美元合同量级不足以形成强短线预期差。
检索:Leidos NHRC 56 million contract materiality revenue market cap recent awards 原文 ↗ - 做多前查反向 · 来源 web · 日期 2019-01-08 · 影响 weakens
2019年已有相近金额NHRC研究支持合同,削弱本次作为全新业务突破的解释。
检索:Leidos previous Naval Health Research Center contract 57.7 million 2019 原文 ↗
先例如何影响了这次决策
对本次决策的影响:由于先例证据不足且当前合同量级偏小,最终压低为AVOID。
方向:未形成可用外部先例样本;同类小额政府服务合同通常需要量级验证后才能判断交易价值。
涨幅量级:没有高相似、锚点干净的先例可校准涨幅。
形态:未完成event_study,不能声称存在稳定上涨或见光死模式。
原文全文
展开原文 · 3,196 字
RESTON, Va., Aug. 25, 2026 /PRNewswire/ -- Leidos (NYSE:LDOS) was recently awarded a contract by the Naval Health Research Center (NHRC) to provide behavioral health research, operational assessments, and data-driven analyses that strengthen the psychological health and operational readiness of members of the U.S. armed services.
The work will focus on identifying risks and protective measures and interventions that affect the health, performance and readiness of military personnel throughout the deployment cycle, while developing evidence-based strategies that enhance resilience, support informed-decision making and reduce adverse outcomes. Leveraging more than 50 years of experience supporting research, Leidos will help NHRC translate scientific findings into practical solutions aimed at improving force readiness and optimizing performance and readiness within the military.
"This program reinforces the need for mission-critical health research in the military community," said Sarah McNichol, vice president of Behavioral Health & Readiness at Leidos Health. "It is vitally important we work to improve warfighter readiness by studying the various psychological factors that can impact military populations."
The NHRC is one of the eight laboratories within the Navy Medical Research & Development Enterprise tasked with optimizing the operational readiness and health of U.S. armed forces through behavioral health, epidemiology, readiness, and disease surveillance. The contract holds a total value of $56 million over a 66-month period of performance.
About Leidos
Leidos is an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations. Headquartered in Reston, Virginia, with approximately 50,000 global employees, Leidos reported annual revenues of approximately $17.2 billion for the fiscal year ended January 2, 2026. For more information, visit www.Leidos.com.
Certain statements in this announcement constitute "forward-looking statements" within the meaning of the rules and regulations of the U.S. Securities and Exchange Commission (SEC). These statements are based on management's current beliefs and expectations and are subject to significant risks and uncertainties. These statements are not guarantees of future results or occurrences. A number of factors could cause our actual results, performance, achievements, or industry results to be different from the results, performance, or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, the "Risk Factors" set forth in Leidos' Annual Report on Form 10-K for the fiscal year ended January 2, 2026, and other such filings that Leidos makes with the SEC from time to time. Readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Leidos does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.
Media contact:
Brandon Ver Velde
(571) 526-6257
[email protected]
SOURCE Leidos Holdings, Inc.
The work will focus on identifying risks and protective measures and interventions that affect the health, performance and readiness of military personnel throughout the deployment cycle, while developing evidence-based strategies that enhance resilience, support informed-decision making and reduce adverse outcomes. Leveraging more than 50 years of experience supporting research, Leidos will help NHRC translate scientific findings into practical solutions aimed at improving force readiness and optimizing performance and readiness within the military.
"This program reinforces the need for mission-critical health research in the military community," said Sarah McNichol, vice president of Behavioral Health & Readiness at Leidos Health. "It is vitally important we work to improve warfighter readiness by studying the various psychological factors that can impact military populations."
The NHRC is one of the eight laboratories within the Navy Medical Research & Development Enterprise tasked with optimizing the operational readiness and health of U.S. armed forces through behavioral health, epidemiology, readiness, and disease surveillance. The contract holds a total value of $56 million over a 66-month period of performance.
About Leidos
Leidos is an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations. Headquartered in Reston, Virginia, with approximately 50,000 global employees, Leidos reported annual revenues of approximately $17.2 billion for the fiscal year ended January 2, 2026. For more information, visit www.Leidos.com.
Certain statements in this announcement constitute "forward-looking statements" within the meaning of the rules and regulations of the U.S. Securities and Exchange Commission (SEC). These statements are based on management's current beliefs and expectations and are subject to significant risks and uncertainties. These statements are not guarantees of future results or occurrences. A number of factors could cause our actual results, performance, achievements, or industry results to be different from the results, performance, or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, the "Risk Factors" set forth in Leidos' Annual Report on Form 10-K for the fiscal year ended January 2, 2026, and other such filings that Leidos makes with the SEC from time to time. Readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Leidos does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.
Media contact:
Brandon Ver Velde
(571) 526-6257
[email protected]
SOURCE Leidos Holdings, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。